OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) saw its stock sink early Monday morning following an update from its Phase 2 Alpine study. The company announced an update following a pre-planned January 23 interim efficacy …
Aug. 02, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical ... The decrease was mainly due to a decrease in employee-related costs including stock-based …
Shares of Nasdaq-listed OncoMed Pharmaceuticals Inc. (OMED) were in for a double blow Monday morning ... Following the update, the stock price of OncoMed tanked by 37% to hit a 52-week low of $4.94 per share on Monday morning.
OncoMed Pharmaceuticals Inc. (OMED) announced Monday morning that its Phase 2 trial ... OncoMed gapped open sharply lower Monday and has continued to weaken in early trade. The stock is now down 3.43 at $5.33 with volume at …
NRG Yield (NYLD): Deutsche Bank has a Hold on the stock. OncoMed Pharmaceuticals (OMED): OMED is assigned an Overweight at Piper Jaffray. PMFG Inc (PMFG): Needham has a Hold on the diversified machinery name, as solid …
If you want a Stock Review on INO, ITCI, OMED, or OPHT then come over to http://dailystocktracker.com/register/ and …
If you want a Stock Review on INO, ITCI, OMED, or OPHT then come over to http://dailystocktracker.com/register/ and …
OncoMed Pharmaceuticals (NASDAQ: OMED) surged 80.40% to $25.40 in the pre-market session ... regulator has closed review of Model S incidents. Morgan Stanley named the stock a Top Pick in the auto sector.